Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects with High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Next Previous
Search
Trial Profile

A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects with High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Apr 2025 Results presented in the Ferring Pharmaceuticals media release.
  • 21 Apr 2025 According to a Ferring Pharmaceuticals media release, data from this trial was presented at the 112th Annual Meeting of the Japanese Urological Association (JUA 2025) held April 17-19 in Fukuoka, Japan.
  • 21 Apr 2025 Results presented in the Ferring Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top